NASDAQ:EDIT Editas Medicine Q2 2026 Earnings Report $2.70 -0.02 (-0.74%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$2.75 +0.05 (+1.85%) As of 09/18/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Editas Medicine EPS ResultsActual EPS-$0.15Consensus EPS -$0.27Beat/MissBeat by +$0.12One Year Ago EPSN/AEditas Medicine Revenue ResultsActual Revenue$11.89 millionExpected Revenue$2.85 millionBeat/MissBeat by +$9.04 millionYoY Revenue GrowthN/AEditas Medicine Announcement DetailsQuarterQ2 2026Date8/5/2026TimeAfter Market ClosesConference Call DateWednesday, August 5, 2026Conference Call Time4:00PM ETUpcoming EarningsEditas Medicine's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 3, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Editas Medicine Earnings HeadlinesEditas Medicine Inc 8EMSeptember 15, 2026 | morningstar.comMReviewing Editas Medicine (NASDAQ:EDIT) & Iovance Biotherapeutics (NASDAQ:IOVA)September 12, 2026 | americanbankingnews.comTrump and Bernie agree on thisDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.September 20 at 1:00 AM | Porter & Company (Ad)Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by AnalystsSeptember 10, 2026 | americanbankingnews.comEditas Medicine Reports Inducement Grants to New Chief Medical OfficerSeptember 9, 2026 | finance.yahoo.comEditas Medicine Reports Inducement Grants to New Chief Medical OfficerSeptember 9, 2026 | globenewswire.comSee More Editas Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Editas Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Editas Medicine and other key companies, straight to your email. Email Address About Editas MedicineEditas Medicine (NASDAQ:EDIT) is a clinical-stage biotechnology company developing gene-editing medicines for serious diseases. The company uses CRISPR-based technologies, including CRISPR/Cas12a and CRISPR/Cas9, to make targeted changes to DNA with the goal of treating the underlying causes of disease rather than only managing symptoms. Editas’ lead program is reni-cel, formerly known as EDIT-301, an investigational ex vivo gene-editing therapy being studied for sickle cell disease and transfusion-dependent beta thalassemia. The company has also pursued in vivo gene-editing programs for inherited retinal disorders and other conditions, although its pipeline may change as clinical and strategic priorities evolve. Founded in 2013 and headquartered in Cambridge, Massachusetts, Editas conducts research and clinical development primarily in the United States, with clinical studies potentially involving patients and research partners in additional regions. The company is led by President and Chief Executive Officer Gilmore O’Neill. Editas Medicine trades on the Nasdaq under the symbol EDIT.View Editas Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
